Description

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is primarily involved in the development, production, and sale of pharmaceutical goods across the People's Republic of China. Its product range targets key therapeutic areas such as antiviral treatments, endocrine and metabolic conditions, and cardiovascular ailments. In addition to finished pharmaceuticals, the company also manufactures active pharmaceutical ingredients, conducts research and development for medical devices, new drugs, and biotechnology, and provides medical consulting services. Their products reach hospitals and various medical institutions via a comprehensive network of distributors. The company has established important strategic collaborations, notably a framework agreement with Alibaba Health Technology (China) Limited for influenza-related projects, and partnerships with Jointown Pharmaceutical Group Co., Ltd., Guangdong Yihao Pharmaceutical Co., Ltd., Shenzhen HEC Industrial Development Co., Ltd., and China National Accord Medicines Corporation Ltd. Founded in 2001 and based in Yichang, China, the company adopted its current name in May 2015, having previously been known as Yichang Changjiang Pharmaceutical Company Limited. It operates as a subsidiary of Guangdong HEC Technology Holding Co., Ltd.